Description

In the 16th episode of BYOB: The Healthcare Podcast, the team sits down to speak with the founder of Ash Wellness. David Stein speaks about what led him to create a company that offered inclusive and accessible healthcare by enabling providers and businesses to provide at-home diagnostics care to their patients. He shares his personal story, experiences of others and how Ash hopes to change the end-to-end experience of at home diagnostic testing.

David Stein – Co-founder and CEO of Ash Wellness

David Stein is the CEO of Ash Wellness, a B2B at-home diagnostic company launching remote care services for healthcare organizations and D2C businesses. Ash Wellness offers white-labeled operations management, testing via a CLIA/CAP certified lab network, kitting and fulfillment, and modern technology infrastructure. In his role, David is responsible for mission vision, strategy oversight, fundraising, and corporate development. He is a graduate of the Cornell Tech MBA program. David lives in New York City, and is passionate about parties and healthcare access.

The crew asked David the following questions:

• For our listeners who may not be aware, can you speak to the great work that Ash Wellness does and what it is?
• Your background has been in myriad of avenues in healthcare, can you talk to us about what led to your decisions to follow the opportunities to start Ash Wellness?
• You mentioned how Ash started with the LGBTQ+ community, is that who you are still primarily focused on right now?
• This past month, we celebrated National LGBTQ Health Awareness week, can you talk about what this week means and where we are in this journey?
• How has the pandemic changed Ash’s business model and the overall business?
• How have partnerships allowed Ash to expand their services?
• How did the Chipotle app inform the design of at-home diagnostics testing?
• What advice would you give to early careerists in healthcare?
• Are there any specific hard or soft skills that you picked up at the first job or in grad school that you would recommend to listeners?

In this week’s episode of Talking with Nakin, we look back at a previous episode that examined the antiviral pills by Merck and Pfizer. The guys discuss what continued options to combat COVID-19 look like as the pandemic evolves.

As more data has come out there are large discrepancies in the effectiveness of Molnupiravir and Paxlovid. The US government has spent over $2B on Molnupiravir and many hospitals are no longer willing to use it while Paxlovid has a lot of restrictions as to who can take it and what it cannot be taken with.

Grab a drink and join us for another episode of BYOB: The Healthcare Podcast!